Table 11Summary HbA1c results in DPP-4 trials

StudyStudy ArmHbA1c (%)baselineHbA1c (%) EndChange from baseline (%)Difference between groups at end (DPP-4 inhibitor - Comparator)P value between groups% achieving Hba1c <7%
Bolli 2008Vildagliptin + metformin8.4%− 0.88% (+/− 0.5%*)0.10% (95% CI − 0.05 to −0.26)27%
Pioglitazone + metformin8.4%− 0.98% (+/−0.06%*)36%
Hermansen 2007Sitagliptin + metformin + glimepiride8.27%−0.59%−0.89<0.00122.6%
Metformin + glimepiride8.26%+ 0.30%1.0%
Nauck 2007Sitagliptin + metformin7.7% (all)6.86% (PP)− 0.67%− 0.02NS63%
Glipizide + metformin7.6%6.84%− 0.67%59%
Scott 2007Sitagliptin + metformin7.8%7.01%− 0.79%+ 0.07NS55%
Rosiglitazone + metformin7.7%6.94%− 0.76%63%
*

Standard Errors as reported by authors. The different sized SEs look odd. It may be the 0.5% for the vildagliptin group which is wrong – it looks that way from the graph of HbA1c in the paper. It should perhaps be 0.05%?

Standard Errors as reported by authors. The different sized SEs look odd. It may be the 0.5% for the vildagliptin group which is wrong – it looks that way from the graph of HbA1c in the paper. It should perhaps be 0.05%?

From: 3, The DPP-4 inhibitors

Cover of Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement)
Newer Agents for Blood Glucose Control in Type 2 Diabetes (Supplement) [Internet].
NICE Clinical Guidelines, No. 87S.
Waugh N, Cummins E, Royle P, et al.
Copyright © 2009, National Institute for Health and Clinical Excellence.

All rights reserved. This material may be freely reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the express written permission of NICE.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.